Pharma's presidential picks

In an industry known for backing Republicans, Sen. Barack Obama has emerged as a surprising pharma favorite in the US presidential election. In April, Obama won a mock election at the annual DTC national meeting, a drug advertising conference, with a 53% to 46% victory over Sen. John McCain. Drug companies have also put the money where their mouth is: Pharma has donated three times more to the Obama campaign than to McCain's. According to a linkurl:Bloomberg News report;http://www.bloomber

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
In an industry known for backing Republicans, Sen. Barack Obama has emerged as a surprising pharma favorite in the US presidential election. In April, Obama won a mock election at the annual DTC national meeting, a drug advertising conference, with a 53% to 46% victory over Sen. John McCain. Drug companies have also put the money where their mouth is: Pharma has donated three times more to the Obama campaign than to McCain's. According to a linkurl:Bloomberg News report;http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aRCVqfSQ43Eo citing data from the Center for Responsive Politics (CRP), pharma execs and employees have donated $450,094 to Obama, compared to $132,575 to McCain. CRP's Web site also lists linkurl:figures;http://www.opensecrets.org/industries/recips.php?cycle=2008&ind=H04 for donations that include pharmaceutical companies and makers of medical devices and other health-related products: Obama is ranked as the top recipient of donations in that category with $848,001, while McCain is in fourth place (behind Clinton and Romney) with $347,375. It's a clear contrast to the 2004 election, in which drug industry donations to George W. Bush almost doubled those to John Kerry. This year's top pharma donations come from Pfizer, Amgen, and Johnson & Johnson, according to CRP's website. Republican lobbyist John Feehery told Bloomberg the lack of industry funding helps McCain, solidifying his reputation as someone who fights special interests. "He goes after these companies and they don't like it." In a linkurl:recent CNBC article,;http://www.cnbc.com/id/26220788 analysts at Stratega Research Partners forecast that both Obama and McCain would be bad for big pharma because of their support for government regulation of Medicare drugs and reimportation, buy-back of American made drugs at abroad prices. Both candidates are expected to be positive forces for generics as the two men endorse moving drugs to the market faster, the article notes. For more on science in the upcoming election, stay tuned for our September issue and accompanying online content, for a look at key thought leaders poised to influence science policy during the next administration, and featuring a round-up of how the candidates stack up on science-related issues. August 19: This blog has been updated from a previous version
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Megan Scudellari

    This person does not yet have a bio.
Share
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Artificial Inc. Logo

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Sapient Logo

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Bio-Rad Logo

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Scientist holding a blood sample tube labeled Mycoplasma test in front of many other tubes containing patient samples

Accelerating Mycoplasma Testing for Targeted Therapy Development